NVision Quantum Technologies, a quantum technology company, today announced the deployment of its POLARIS™ platform at Hokkaido University. Installed at the Graduate School of Information Science and Technology’s Division of Bioengineering and Bioinformatics, the system marks NVision’s first deployment in Japan and establishes Hokkaido University as a key research partner in the Asia-Pacific region. The deployment follows a year of international expansion for NVision’s quantum-enhanced MRI business. NVision now works with leading research institutions including the University of Cambridge, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, and the Technical University of Munich. In Asia, the company is also collaborating with Yonsei University in South Korea through the RESQ research project. Hokkaido University is internationally recognized for its research in metabolic imaging and hyperpolarization technologies, with a particular focus on understanding how changes in metabolism reflect disease biology and treatment response. The deployment expands NVision's global research network while strengthening the company's research presence in Japan and across the Asia-Pacific region. “Quantum technology only creates value when it is placed in the hands of researchers who can turn it into meaningful scientific and clinical progress,” said Dr. Sella Brosh, CEO of NVision. “We are proud to be building a global community of leading scientists who are applying quantum-enhanced MRI to important questions in medicine and drug development. Hokkaido University brings deep expertise in hyperpolarization and metabolic imaging, and this deployment gives us a strong foundation for expanding our work in Japan and across Asia.” POLARIS boosts the MRI signal of sugars over 10,000x through a process known as hyperpolarization, making it possible for standard MRI systems to “light up” and measure cell metabolism in real time. It is the first commercially available quantum-based polarizer, using parahydrogen-induced polarization, or PHIP, to produce a metabolic imaging agent in under three